Clinical Trial Update: Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence [Phase 3]

View source ↗

Summary

Phase 3 trial of masitinib in localized, high-risk gastrointestinal stromal tumor after complete surgery was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Gastro-Intestinal Stromal Tumour | Phase 3 | Status: TERMINATED